This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amarin's (AMRN) Q4 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) strong revenue growth in the fourth quarter is driven by solid demand for its cardiovascular drug, Vascepa.
Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Clovis (CLVS) reports mixed fourth-quarter 2019 results. The company's sole marketed drug, Rubraca, drives revenues. Shares down.
The Zacks Analyst Blog Highlights: Visa, JPMorgan Chase, Bank of America, AstraZeneca and Duke Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, JPMorgan Chase, Bank of America, AstraZeneca and Duke Energy
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
by Kinjel Shah
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Progress of its pipeline candidates is likely to have increased Moderna's (MRNA) operating expenses in the fourth quarter.
Top Stock Reports for Visa, JPMorgan & Bank of America
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), JPMorgan Chase (JPM) and Bank of America (BAC).
Roche's Tecentriq sBLA for Lung Cancer Gets Priority Review
by Kinjel Shah
Roche (RHHBY) gets FDA's priority review status for a sBLA for Tecentriq monotherapy in first-line treatment of certain people with advanced non-small cell lung cancer.
Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.
AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.
Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study
by Zacks Equity Research
Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.
FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA
by Zacks Equity Research
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Incyte's (INCY) NDA for capmatinib and grants Priority Review.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.
Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates
by Kinjel Shah
Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
What's in Store for Ironwood (IRWD) This Earnings Season?
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.
Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off
by Zacks Equity Research
Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.
Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven Q4 sales. However, genericization of key drugs and increased competition might have been concerns.
Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.
Allergan to Divest Brazikumab, Zenpep to Close AbbVie Merger
by Zacks Equity Research
Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.
Roche's Urothelial Cancer Study on Tecentriq Disappoints
by Zacks Equity Research
Roche's (RHHBY) study on Tecentriq in muscle-invasive urothelial cancer fails to meet goals.
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU
by Kinjel Shah
J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.
5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Top Stock Research Reports for Roche, Royal Dutch Shell & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Roche Holding (RHHBY), Royal Dutch Shell (RDS.A) and Citigroup (C).